Welcome to our dedicated page for Myriad Genetics news (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Myriad Genetics Inc. reports developments in molecular diagnostic testing and precision medicine, with recurring updates on tests that assess disease risk, disease progression, and treatment selection across medical specialties. Company news commonly covers the Cancer Care Continuum, Prenatal Health, and Mental Health businesses, including test volume trends, average revenue per test, earnings results, and financial guidance.
Updates also address Myriad's oncology diagnostics and research programs, including MyChoice CDx, Precise MRD, Prolaris, hereditary cancer testing, GeneSight, and prenatal testing products. News themes include companion diagnostic approvals, clinical data presentations, commercial launches, collaborations, and investor healthcare conference participation.
Myriad Genetics (NASDAQ: MYGN) announced FDA approval for its BRACAnalysis CDx test, a companion diagnostic for identifying men with metastatic castration-resistant prostate cancer (mCRPC) eligible for Lynparza (olaparib) treatment. This marks the seventh regulatory approval for the test, enhancing treatment options for patients with BRCA1/BRCA2 mutations. The PROfound trial demonstrated significant improvement in progression-free survival for patients treated with Lynparza compared to standard therapies. Myriad aims to improve patient outcomes through precision medicine.
Myriad Genetics (MYGN) announced FDA approval for its myChoice CDx test, a companion diagnostic for identifying advanced ovarian cancer patients with homologous recombination deficiency (HRD) who are eligible for first-line maintenance treatment with Lynparza (olaparib) and bevacizumab. The approval enhances precision medicine, potentially benefiting one in two women with HRD-positive ovarian cancer. Myriad's collaboration with AstraZeneca since 2007 continues to foster advancements in cancer diagnostics.